Genelux Corp (GNLX)

$2.45

-0.17

(-6.49%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $2.39
    $2.66
    $2.45
    downward going graph

    2.65%

    Downside

    Day's Volatility :10.34%

    Upside

    7.89%

    downward going graph
  • $1.71
    $30.44
    $2.45
    downward going graph

    30.2%

    Downside

    52 Weeks Volatility :94.38%

    Upside

    91.95%

    downward going graph

Returns

PeriodGenelux CorpIndex (Russel 2000)
3 Months
-36.53%
0.0%
6 Months
-80.37%
0.0%
1 Year
-91.52%
0.0%
3 Years
-60.16%
-18.2%

Highlights

Market Capitalization
91.4M
Book Value
$0.57
Earnings Per Share (EPS)
-0.92
Wall Street Target Price
23.5
Profit Margin
0.0%
Operating Margin TTM
-101437.5%
Return On Assets TTM
-82.14%
Return On Equity TTM
-290.1%
Revenue TTM
8.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-95.3%
Gross Profit TTM
11.1M
EBITDA
-25.4M
Diluted Eps TTM
-0.92
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.84
EPS Estimate Next Year
-1.08
EPS Estimate Current Quarter
-0.23
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Genelux Corp(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 859.18%

Current $2.45
Target $23.50

Technicals Summary

Sell

Neutral

Buy

Genelux Corp is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Genelux Corp
Genelux Corp
3.38%
-80.37%
-91.52%
-60.16%
-60.16%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Genelux Corp
Genelux Corp
NA
NA
NA
-0.84
-2.9
-0.82
NA
0.57
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Genelux Corp
Genelux Corp
Buy
$91.4M
-60.16%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Genelux Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.46M → 8.0K (in $), with an average decrease of 99.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -5.34M → -7.85M (in $), with an average decrease of 21.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 160.5%

Company Information

Organization
Genelux Corp
Employees
23
CEO
Mr. Thomas Zindrick J.D.
Industry
Miscellaneous

FAQs